TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05913427
Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.).
Study: NCT05623904
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.
Study: NCT06474273
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Methylprednisolone
Study: NCT06474273
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone augmentation
Study: NCT06103695
Drug: Tapinarof
Normalized name: Tapinarof
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add on Vtama (tapinarof) to biololgic therapy
Study: NCT06553339
Drug: Oral HS-10516
Normalized name: estrogens, esterified (USP)
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIF-2α inhibitor
Study: NCT05870683
Drug: Tegoprazan
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Included in dual eradication medication.
Study: NCT05870683
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included in dual eradication medication.
Study: NCT05870683
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Included in dual eradication medication.
Study: NCT05053087
Drug: Ropivacaine Continuous Infusion
Normalized name: Uniphyllin Continus
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% continuous infusion 6mL/hr
Study: NCT05157672
Drug: Nicotine gum (2.5 mg)
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gum, 2.5 mg
Study: NCT05157672
Drug: Letrozole (2.5 mg)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet, 2.5 mg
Study: NCT04030052
Drug: Nuwiq (low dose protocol)
Normalized name: Nuwiq
DrugBank: Simoctocog alfa (DB09108)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
Study: NCT04030052
Drug: HEMLIBRA
Normalized name: Hemlibra
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
Study: NCT05053087
Drug: Ropivacaine Intermittent Bolus
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% intermittent bolus infusion 8mL every 2 hours
Study: NCT04885829
Drug: Tocilizumab Prefilled Syringe
Normalized name: tocilizumab Prefilled Syringe
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
Study: NCT04030052
Drug: Nuwiq (Atlanta protocol)
Normalized name: Nuwiq
DrugBank: Simoctocog alfa (DB09108)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
Study: NCT05480787
Drug: Remimazolam 0.1mg/kg/h
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam Tosilate for Injection(36mg)
Study: NCT05480787
Drug: Remimazolam 0.3mg/kg/h
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam Tosilate for Injection(36mg)
Study: NCT05480787
Drug: Remimazolam 0.5mg/kg/h
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam Tosilate for Injection(36mg)
Study: NCT03306615
Drug: Hyaluronidase
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
Study: NCT06376916
Drug: Magnesium Sulfate 2 G
Normalized name: magnesium sulfate 2 GM in 50 ML Injection
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Study: NCT06376916
Drug: Magnesium Sulfate 4 G
Normalized name: magnesium sulfate 4 GM in 50 ML Injection
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Study: NCT06376916
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Study: NCT06101394
Drug: Cetuximab-IRDye800
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
Study: NCT04786873
Drug: Macimorelin
Normalized name: Macimorelin
DrugBank: Macimorelin (DB13074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
Study: NCT04718181
Drug: risdiplam
Normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
Study: NCT04718181
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
Study: NCT05999474
Drug: Topical tioconazole
Normalized name: tioconazole Topical Product
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laser
Study: NCT04693897
Drug: Mirabegron 50 MG
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
Study: NCT04693897
Drug: Solifenacin Succinate 5 MG
Normalized name: solifenacin succinate 5 MG
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
Study: NCT00000741
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04735367
Drug: palbociclib plus letrozole
Normalized name: Palbociclib
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib plus letrozole
Study: NCT05014594
Drug: Dapagliflozin (10Mg Tab) along with standard medical therapy
Normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
Study: NCT06308939
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.4mg/m\^2 day1、8，repeated every 3 week.
Study: NCT06308939
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg once every three weeks.
Study: NCT05418244
Drug: Oral Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg oral disintegrating ondansetron tablet once
Study: NCT00002058
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04398719
Drug: Low-dose lipopolysaccharide
Normalized name: ethinyl estradiol
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive intravenous lipopolysaccharide.
Study: NCT04398719
Drug: Intradermal Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A small dose of capsaicin will be administered by intradermal injection.
Study: NCT06520176
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1\~Day 2: 75mg/m\^2
Study: NCT06520176
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1\~Day 2: 200g/m\^2, q12h
Study: NCT06520176
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Day 6: 6mg
Study: NCT06520176
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.
Study: NCT06520176
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study: NCT05118386
Drug: RSM01
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM
Study: NCT05604989
Drug: intravitreal Anti-VEGF injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
Study: NCT00006630
Drug: Vaccinia Immune Globulin (Human)
Normalized name: Vaccinia Immune Globulin (Human) Intravenous
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04671914
Drug: Hyaluronic Acid 20 MG/ML Injectable Solution
Normalized name: hyaluronic acid 20 MG/ML Injectable Solution
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
Study: NCT06434103
Drug: SHR-A1921；Adebrelimab；SHR-8068；carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
Study: NCT05087602
Drug: Toripalimab and Anlotinib
Normalized name: Toripalimab
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study: NCT00000728
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000728
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06553456
Drug: Human Serum Albumin
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The positive control drug was administered at a dose of 20 g/ day for 7 days.
Study: NCT04657016
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05249231
Drug: Silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
Study: NCT05161351
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
Study: NCT05161351
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be vitamin D3, (colecalciferol).
Study: NCT05582811
Drug: Dose Riociguat 2,5 or 5mg
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A selective stimulator of soluble guanylate cyclase (sGC)
Study: NCT05582811
Drug: Riociguat
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A selective stimulator of soluble guanylate cyclase (sGC)
Study: NCT05201859
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
Study: NCT06548945
Drug: GZR18
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg-maximum tolerated dose (MTD), single dose
Study: NCT06324994
Drug: Linperlisib in combination with Obinutuzumab and Venetoclax
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.
Study: NCT06553924
Drug: Macitentan and Tadalafil film-coated tablets
Normalized name: macitentan and tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study: NCT05397886
Drug: Remimazolam Besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
Study: NCT05397886
Drug: Flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
Study: NCT05397886
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
Study: NCT04820205
Drug: Intranasal dexmedetomidine and ketamine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
Study: NCT04820205
Drug: Oral chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
Study: NCT05491057
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib standard dose 240 mg once daily for 1 year
Study: NCT06549855
Drug: Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day
Study: NCT04891991
Drug: Intravitreal infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
Study: NCT05744115
Drug: Ga-68-PSMA-11
Normalized name: Ga-68 PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
Study: NCT05060666
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~* 15 mg for 40-60 kg = 5 tablets à 3 mg~* 18 mg for 60-80 kg = 6 tablets à 3 mg~* 24 mg for \> 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg.
Study: NCT04964219
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval.
Study: NCT00096837
Drug: Motexafin Gadolinium Injection
Normalized name: gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05841134
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months.
Study: NCT05304871
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion
Study: NCT05769842
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
Study: NCT06336096
Drug: Suzetrigine
Normalized name: Suzetrigine
DrugBank: Suzetrigine (DB18927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) for oral administration.
Study: NCT06336096
Drug: Suzetrigine
Normalized name: Suzetrigine
DrugBank: Suzetrigine (DB18927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) and Suspension for oral administration.
Study: NCT05525767
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.